Contrive Datum Insights has published "Mixed Mode Chromatography Resin Market Size, Share & Industry Analysis, By Type (Ion Exchange-Hydrophobic Type, Hydroxyapatite Type), Application (Monoclonal Antibodies, Non-antibody Protein, Polyclonal Antibodies, Separation of Low Molecular Weight Impurities, Vaccine Production, Others), End user (Biopharmaceutical Manufacturers, Contract Manufacturing Organizations (CMOs/CDMOs), Academic and Research Institutes), Base matrix (Agarose-based, Polymethacrylate-based, Silica-based), Mode of operation (Bind-and-Elute Mode, Flow-Through Mode), and Regional Forecast, 2026-2034". The study sizes the global mixed mode chromatography resin market at USD 2.95 billion in 2025 and projects growth from USD 3.23 billion in 2026 to USD 6.66 billion by 2034, a compound annual growth rate of 9.46% across the forecast period.
Mixed mode chromatography resin is a solid-phase purification medium engineered with more than one distinct binding chemistry, most commonly a combination of ion exchange and hydrophobic interaction, or hydroxyapatite mineral chemistry, packed into a single resin bead. It is used inside a purification column to separate a target protein from closely related impurities, such as charge variants, aggregates and host cell proteins, in a single processing step that a single-mode resin cannot achieve alone. Buyers are biopharmaceutical manufacturers, contract manufacturing and development organizations, and academic or research laboratories that purify proteins, antibodies or vaccines at bench, pilot or commercial scale.
Rising Monoclonal Antibody and Biosimilar Production Volumes
Rising Monoclonal Antibody and Biosimilar Production Volumes is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.46% a year, the type lines exposed to it move fastest: Hydroxyapatite Type compounds at 10.66%, taking its share of revenue from 23.4% to 26% and its value from USD 0.69 billion to USD 1.73 billion.
Where the forecast could be beaten: faster approval and commercial launch of monoclonal antibody and biosimilar programs, combined with quicker-than-expected capacity additions by contract manufacturers in Asia Pacific, pull resin demand forward relative to the base case. The study puts that case at USD 7.33 billion in 2034, against USD 6.66 billion in the base.
Against that, broader and earlier-than-expected adoption of flow-through purification modes, which use less resin per batch, combined with slower biosimilar approval activity, holds resin demand below the base case. On that reading 2034 revenue stops at USD 5.99 billion. The weight of the problem sits in Ion Exchange-Hydrophobic Type: 76.6% of 2025 revenue growing at 9.08%, well under the market's 9.46%.
Ion Exchange-Hydrophobic Type Scale Against Hydroxyapatite Type Momentum
The type axis, not the regional one, is what divides the field. Ion Exchange-Hydrophobic Type is the volume position, 76.6% of 2025 revenue at USD 2.26 billion, holding 74% through 2034, and it is defended by scale. Hydroxyapatite Type is the growth position at 10.66%, and it is open. Strength in one does not carry into the other.
Additional Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Application | Monoclonal Antibodies | 51.53% · USD 1.52 billion | Vaccine Production 12.37% |
| End user | Biopharmaceutical Manufacturers | 62.37% · USD 1.84 billion | Contract Manufacturing Organizations (CMOs/CDMOs) 11.04% |
| Base matrix | Agarose-based | 54.92% · USD 1.62 billion | Polymethacrylate-based 10.58% |
| Mode of operation | Bind-and-Elute Mode | 82.03% · USD 2.42 billion | Flow-Through Mode 12% |
- Based on regional analysis, North America led the global mixed mode chromatography resin market in 2025 with 42% of global revenue at USD 1.23 billion, reaching USD 2.53 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22% in 2025 to 27% in 2034, with revenue growing from USD 0.65 billion to USD 1.8 billion.
- Middle East and Africa remains the smallest region throughout, at 3% of 2025 revenue and 3% by 2034.
- By type, the largest line in 2025 was Ion Exchange-Hydrophobic Type, at 76.6% of revenue and USD 2.26 billion.
- No type line grows faster than Hydroxyapatite Type, at a projected 10.66%.
- The United States is the largest single country market at USD 0.98 billion in 2025, 33.22% of global revenue.
The study covers five axes, by type, and by application, end user, base matrix and mode of operation, reporting revenue and a growth rate for every line in every year from 2020 to 2034, with bear, base and bull scenarios on the headline total at USD 5.99 billion and USD 7.33 billion by 2034. Country-level detail is given for all five regions, together with the competitive landscape and the research methodology. Delivered as a PDF; request a free sample to review it.